Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxacom in Pulmonary Arterial Hypertension
NCT06683040Phase 3Active, not recruiting
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of Oxacom in pulmonary arterial hypertension (PAH). Started Jun 2024; status: active, not recruiting.
02
Drugs
Oxacom
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06683040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683040.